论文部分内容阅读
目的探究轮状病毒肠炎采用肠泰合剂联合思密达治疗的临床效果。方法资料随机选取2013年8月~2014年8月于本院诊治的轮状病毒肠炎患儿93例,随机分为研究组47例,对照组46例;对照组予以常规治疗,研究组予以肠泰合剂联合思密达治疗,分析两组患儿不良反应情况和症状改善时间。结果研究组患儿的症状改善时间短于对照组,差异具有统计学意义(P<0.05);且两组患儿均无明显不良反应发生(P>0.05)具有可比性。结论肠泰合剂联合思密达治疗轮状病毒肠炎患儿的疗效显著,安全性较高,具有临床推广价值。
Objective To investigate the clinical effect of treating intestinal rotavirus enteritis combined with Smecta. Methods Data of 93 children with rotavirus enteritis diagnosed and treated in our hospital from August 2013 to August 2014 were randomly divided into study group (n = 47) and control group (n = 46). The control group Thai mixture agent combined with Smectite treatment, analysis of adverse reactions in children with two groups and symptoms to improve time. Results The symptom improvement time in study group was shorter than that in control group, with statistical significance (P <0.05). There was no obvious adverse reaction in both groups (P> 0.05). Conclusion Intestinal trihydrate agent combined with Smectite treatment of children with rotavirus enteritis has a significant effect, high safety, with clinical value.